Benito Enterprises, Parent Company of Lazarus Labs, Announces the Release of a New Non-prescription Blood Sugar and Diabetes Control Product
A breakthrough in blood sugar control and diabetes relief. Lazarus Labs announced the release of Glycemil (tm) a non-prescription product clinically proven to help control blood sugar levels without dangerous side effects.
Atlanta, GA (PRWEB) March 10, 2006
A new breakthrough in blood sugar control was announced today with the release of a non-prescription blood sugar control and diabetes relief formula trade named Glycemil™. A spokesperson for Lazarus Labs, a non-prescription pharmaceutical firm, said Glycemil ™ was produced in response to the alarming increase in the incidence of diabetes and high blood sugar levels in patients in the U. S.
High blood sugar (glucose) levels are associated with a number of serious health problems including obesity, heart disease and diabetes. Diabetes is a disease characterized by the body’s inability to properly regulate levels of blood sugar by producing or adequately utilizing insulin. It affects over 20,000,000 people in the U. S. alone and is associated with an increased risk of life-threatening complications such as a heart attack, stroke, and/or kidney disease. At present, diabetes is the third leading cause of death in the United States.
According to Arley Vest, CEO of Benito Enterprises and Lazarus Labs, Glycemil™ is a pharmaceutical grade non-prescription formula clinically proven to help control blood sugar levels without dangerous side effects. Glycemil™ is specifically formulated to help prevent the health problems associated with high blood sugar levels by helping to blunt the “insulin spike” caused by high glycemic index foods as well as helping regulate blood sugar levels, lowering insulin resistance, and helping regulate insulin production.
For more information, contact Arley Vest, Benito Enterprises, 770-606-1002 or email at avest@lazaruslabs. com.
###
